The clinical observation of hepatic toxicity in hepatitis B virus markers positive cancer patients undergoing chemotherapy
10.3760/cma.j.issn.1673-4904.2013.13.008
- VernacularTitle:乙型肝炎病毒标志物阳性与恶性肿瘤患者化疗后肝损害的临床关系研究
- Author:
Huahuang LING
;
Tao LI
;
Xiangcheng WU
;
Ximei HUANG
;
Maode CAI
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Neoplasms;
Chemotherapy;
Hepatic toxicity
- From:
Chinese Journal of Postgraduates of Medicine
2013;(13):28-31
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the liver damage induced by chemotherapy in patients with cancer and positive for hepatitis B virus (HBV) markers.Methods From January 2005 to January 2012,913 cancer patients were treated by chemotherapy including HBV-positive patients (HBV-positive group,288 cases) and HBV-negative patients (HBV-negative group,625 cases).The changes of hepatic function after chemotherapy between two groups were compared.Results The incidence of hepatic toxicity in HBV-positive group was higher than that in HBV-negative group [24.0％ (69/288) vs.11.4％ (71/625)],and there was significant difference between two groups (P＜ 0.01).The incidence of degree 11Ⅲ-Ⅳ hepatic toxicity was 11.4％ (14/123) in HBV-DNA-positive patients and 0.6％ (4/625) in HBV-negative group.In a variety of chemotherapy,there was significant difference in the incidence of hepatic toxicity in TP(paclitaxel +cisplatin),CAF(cyclophosphamide + doxorubicin + fluorouracil),CHOP(cyclophosphamide + doxorubicin +vincristine + prednisone) between two groups (P ＜ 0.05).The incidence of hepatic toxicity was highest in TP,which was 34.6％ (18/52) in HBV-positive group and 16.5％ (20/121) in HBV-negative group.Conclusion HBV infection is associated with higher risk of hepatic toxicity in patients with cancer during chemotherapy.
